News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,613 Results
Type
Article (46142)
Company Profile (303)
Press Release (668168)
Section
Business (208953)
Career Advice (2230)
Deals (36280)
Drug Delivery (106)
Drug Development (82547)
Employer Resources (174)
FDA (16298)
Job Trends (15226)
News (352735)
Policy (33174)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (8)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (8)
2024 Pharm Country Standard (6)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2576)
Accelerated approval (2)
Adcomms (25)
Allergies (78)
Alliances (50883)
ALS (81)
Alzheimer's disease (1345)
Antibody-drug conjugate (ADC) (109)
Approvals (16273)
Artificial intelligence (224)
Autoimmune disease (13)
Automation (14)
Bankruptcy (367)
Best Places to Work (11735)
BIOSECURE Act (19)
Biosimilars (94)
Biotechnology (223)
Bladder cancer (52)
Brain cancer (25)
Breast cancer (234)
Cancer (1838)
Cardiovascular disease (142)
Career advice (1846)
Career pathing (30)
CAR-T (141)
Cell therapy (401)
Cervical cancer (13)
Clinical research (66554)
Collaboration (737)
Compensation (393)
Complete response letters (23)
COVID-19 (2618)
CRISPR (35)
C-suite (188)
Cystic fibrosis (100)
Data (1730)
Decentralized trials (2)
Denatured (18)
Depression (41)
Diabetes (224)
Diagnostics (6368)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (107)
Drug pricing (100)
Drug shortages (24)
Duchenne muscular dystrophy (66)
Earnings (86605)
Editorial (30)
Employer branding (21)
Employer resources (151)
Events (115032)
Executive appointments (605)
FDA (17283)
Featured Employer (53)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (654)
Gene editing (93)
Generative AI (21)
Gene therapy (283)
GLP-1 (692)
Government (4416)
Grass and pollen (4)
Guidances (46)
Healthcare (18931)
Huntington's disease (24)
IgA nephropathy (21)
Immunology and inflammation (98)
Indications (24)
Infectious disease (2741)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (43)
Intellectual property (72)
Interviews (355)
IPO (16783)
IRA (42)
Job creations (3927)
Job search strategy (1589)
Kidney cancer (10)
Labor market (26)
Layoffs (460)
Leadership (17)
Legal (8098)
Liver cancer (68)
Lung cancer (261)
Lymphoma (121)
Machine learning (2)
Management (60)
Manufacturing (260)
MASH (58)
Medical device (13334)
Medtech (13339)
Mergers & acquisitions (19896)
Metabolic disorders (601)
Multiple sclerosis (62)
NASH (18)
Neurodegenerative disease (79)
Neuropsychiatric disorders (27)
Neuroscience (1800)
NextGen: Class of 2025 (6670)
Non-profit (4524)
Northern California (2244)
Now hiring (36)
Obesity (329)
Opinion (240)
Ovarian cancer (62)
Pain (75)
Pancreatic cancer (71)
Parkinson's disease (121)
Partnered (18)
Patents (184)
Patient recruitment (82)
Peanut (46)
People (58614)
Pharmaceutical (69)
Pharmacy benefit managers (18)
Phase I (20831)
Phase II (29369)
Phase III (21733)
Pipeline (832)
Podcasts (60)
Policy (108)
Postmarket research (2587)
Preclinical (8787)
Press Release (72)
Prostate cancer (84)
Psychedelics (35)
Radiopharmaceuticals (245)
Rare diseases (357)
Real estate (6254)
Recruiting (66)
Regulatory (22484)
Reports (43)
Research institute (2370)
Resumes & cover letters (376)
Rett syndrome (2)
RNA editing (1)
RSV (38)
Schizophrenia (62)
Series A (121)
Series B (73)
Service/supplier (14)
Sickle cell disease (53)
Southern California (1912)
Special edition (14)
Sponsored (29)
Startups (3826)
State (2)
Stomach cancer (12)
Supply chain (58)
The Weekly (41)
United States (19783)
Vaccines (653)
Venture capitalists (35)
Webinars (12)
Weight loss (231)
Women's health (30)
Worklife (15)
Date
Today (171)
Last 7 days (769)
Last 30 days (3020)
Last 365 days (35137)
2025 (5857)
2024 (36003)
2023 (40712)
2022 (51903)
2021 (56378)
2020 (54699)
2019 (47159)
2018 (35603)
2017 (33153)
2016 (32601)
2015 (38467)
2014 (33847)
2013 (28964)
2012 (29451)
2011 (30121)
2010 (28200)
Location
Africa (800)
Alabama (48)
Alaska (7)
Arizona (215)
Arkansas (12)
Asia (39579)
Australia (6647)
California (5115)
Canada (1771)
China (429)
Colorado (233)
Connecticut (245)
Delaware (113)
Europe (86165)
Florida (748)
Georgia (172)
Idaho (57)
Illinois (493)
India (21)
Indiana (278)
Iowa (7)
Japan (129)
Kansas (103)
Kentucky (23)
Louisiana (7)
Maine (59)
Maryland (787)
Massachusetts (3916)
Michigan (202)
Minnesota (357)
Mississippi (2)
Missouri (71)
Montana (30)
Nebraska (26)
Nevada (55)
New Hampshire (61)
New Jersey (1460)
New Mexico (28)
New York (1456)
North Carolina (904)
North Dakota (7)
Northern California (2244)
Ohio (178)
Oklahoma (13)
Oregon (32)
Pennsylvania (1160)
Puerto Rico (6)
Rhode Island (23)
South America (1187)
South Carolina (13)
South Dakota (1)
Southern California (1912)
Tennessee (83)
Texas (748)
Utah (158)
Virginia (120)
Washington D.C. (55)
Washington State (488)
West Virginia (3)
Wisconsin (45)
714,613 Results for "oncolytics biotech inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
February 19, 2025
·
8 min read
Press Releases
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
February 25, 2025
·
2 min read
Press Releases
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
February 9, 2025
·
2 min read
Press Releases
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
February 18, 2025
·
8 min read
Business
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech ® Inc. today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics’ Board of Directors, will serve as the interim CEO during Dr. Coffey’s absence.
June 24, 2024
·
5 min read
Business
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR).
May 15, 2024
·
8 min read
Biotech Beach
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech ® Inc. announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
June 20, 2024
·
9 min read
Policy
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech® Inc. announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration, supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer.
June 27, 2024
·
6 min read
Press Releases
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
January 22, 2025
·
10 min read
Biotech Beach
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting.
May 24, 2024
·
10 min read
1 of 71,462
Next
